Advicenne expects imminent marketing authorization for ADV7103 (Sibnayal™) for dRTA in Europe

March 19, 2021

Paris, France, March 19, 2021 – 6.00 pm CET –  Advicenne (Euronext: ADVIC) (the “Company”), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for rare renal diseases, announced that it anticipates imminent European Marketing Authorization for its lead product, ADV7103 (Sibnayal™).